QUESTIONING TTO FINANCING MODELS: COULD THEIR EXPECTED FINANCIAL OUTCOME BIAS THE TECH TRANSFER PROCESS?
Dr. Michael Motz
Michael has more than twenty years of experience in the pharma and biotech industry and serves currently as the Chief Business Officer of Netris Pharma SA, a Lyon based clinical stage oncology biotech company. Prior to Netris, Michael served as CEO of Algobate AG, which was partnered with a European specialty pharma group as well as in Senior Business Development Leadership functions at Zealand Pharma, Roche, Novartis/Sandoz and ALTANA Pharma. Michael is a chemist by education and did his PhD in protein-protein interactions at the Max Planck Institute and at LION Bioscience AG.